Significance of novel HBV expression vectors in selecting antiviral drugs in clinical therapy / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 8-12, 2007.
Article
in Chinese
| WPRIM
| ID: wpr-285492
ABSTRACT
<p><b>OBJECTIVE</b>To establish a new method for rapidly selecting anti-hepatitis B virus drugs in clinical therapy.</p><p><b>METHODS</b>The full-length hepatitis B virus (HBV) genomes from 8 patients with chronic hepatitis B (CHB) were generated by polymerase chain reaction (PCR). All patients were resistant to lamivudine therapy. Their HBV DNA fragments were inserted into Sap I site of pHY106 eukaryotic expression vector separately. The recombinant plasmids containing 1.1 copies of HBV genome were transfected into Huh7 cell line; the levels of HBsAg, HBeAg and HBV DNA in supernatants of Huh7 cells were measured by ELISA and real-time quantitative PCR, and intracellular HBV replicative intermediates were detected by Southern blot. Antiviral effects of lamivudine and adefovir were evaluated in this vitro system.</p><p><b>RESULTS</b>The 8 recombinant plasmids containing a full-length genome of clinical HBV isolates could replicate and be expressed in Huh 7 cells. There were 6 isolates with polymerase YVDD mutations and 2 isolates with polymerase YIDD mutations. Adefovir, but not lamivudine, inhibited the HBV replication and gene expression in vitro. Furthermore, adefovir inhibited HBV replication in these CHB patients.</p><p><b>CONCLUSION</b>The method described here enables a rapid selection of anti-HBV drugs in clinical therapy and is very useful in antiviral therapy for CHB patients.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Pharmacology
/
Virology
/
Hepatitis B virus
/
Virosomes
/
Drug Resistance, Viral
/
Drug Evaluation, Preclinical
/
Genetics
/
Hepatitis B
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hepatology
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS